|
|
|
Volumn 24, Issue 1 Suppl 5, 1997, Pages
|
|
An overview of the clinical pharmacology of topotecan.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAMPTOTHECIN;
DNA TOPOISOMERASE;
DRUG DERIVATIVE;
ENZYME INHIBITOR;
LACTONE;
TOPOTECAN;
WATER;
CHEMICAL MODEL;
CHEMICALLY INDUCED DISORDER;
CHEMISTRY;
DOSE RESPONSE;
DRUG ANTAGONISM;
FEMALE;
HALF LIFE TIME;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
METABOLIC CLEARANCE RATE;
NEUTROPENIA;
PH;
PHASE 1 CLINICAL TRIAL;
PHYSICAL CHEMISTRY;
REVIEW;
SOLUBILITY;
ANTINEOPLASTIC AGENTS;
CAMPTOTHECIN;
CHEMISTRY, PHYSICAL;
CLINICAL TRIALS, PHASE I;
DNA TOPOISOMERASES, TYPE I;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ENZYME INHIBITORS;
FEMALE;
HALF-LIFE;
HUMANS;
HYDROGEN-ION CONCENTRATION;
INFUSIONS, INTRAVENOUS;
LACTONES;
METABOLIC CLEARANCE RATE;
MODELS, CHEMICAL;
NEUTROPENIA;
SOLUBILITY;
TOPOTECAN;
WATER;
|
|
EID: 0031062384
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (57)
|
|
References (34)
|
